<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02031731</url>
  </required_header>
  <id_info>
    <org_study_id>YO28211</org_study_id>
    <nct_id>NCT02031731</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetics and Safety of Onartuzumab (MetMAb) in Chinese Patients With Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A PHASE I STUDY OF THE PHARMACOKINETICS AND SAFETY OF ONARTUZUMAB IN CHINESE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This phase I study will examine the pharmacokinetics and safety of Onartuzumab (MetMAb) in&#xD;
      chinese patients with locally advanced or metastatic solid tumors. Patients will be divided&#xD;
      into 3 cohorts, which will each be given a different dose of MetMAb. The cohorts will be&#xD;
      treated sequentially, starting with the lowest dose. MetMAb will be administered&#xD;
      intravenously every 3 weeks. Patients may be treated for up to 16 cycles (21 days each) or 1&#xD;
      year, whichever occurs first, in the absence of disease progression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 13, 2014</start_date>
  <completion_date type="Actual">April 14, 2014</completion_date>
  <primary_completion_date type="Actual">April 14, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total exposure of MetMAb, as measured by area under the concentration-time curve (AUC)</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-therapeutic antibodies against MetMAb</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>4 mg/kg Onartuzumab (MetMAb)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>15 mg/kg Onartuzumab (MetMAb)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg/kg Onartuzumab (MetMAb)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4 mg/kg Onartuzumab (MetMAb)</intervention_name>
    <description>4 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.</description>
    <arm_group_label>4 mg/kg Onartuzumab (MetMAb)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>15 mg/kg Onartuzumab (MetMAb)</intervention_name>
    <description>15 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.</description>
    <arm_group_label>15 mg/kg Onartuzumab (MetMAb)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30 mg/kg Onartuzumab (MetMAb)</intervention_name>
    <description>30 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.</description>
    <arm_group_label>30 mg/kg Onartuzumab (MetMAb)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;/= 18 years&#xD;
&#xD;
          -  Histologically confirmed locally advanced or metastatic solid tumor that does not&#xD;
             respond to standard treatment or for which there is no further standard treatment.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status from 0 to 2.&#xD;
&#xD;
          -  Use of effective contraception&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Brain metastasis or spinal cord compression that has not yet been definitively treated&#xD;
             with surgery and/or radiation, and/or patients with brain metastasis that have been&#xD;
             receiving corticosteroids.&#xD;
&#xD;
          -  Previously diagnosed and treated central nervous system (CNS) metastases or spinal&#xD;
             cord compression that has not been clinically stable for at least 2 months.&#xD;
&#xD;
          -  Treatment with anti-tumor therapy within 4 weeks before the start of study treatment,&#xD;
             with the following exception: Patients with metastatic prostate cancer on maintenance&#xD;
             hormonal therapy, provided they meet all other eligibility criteria.&#xD;
&#xD;
          -  Current, serious or uncontrolled, systemic illness.&#xD;
&#xD;
          -  Recent stroke (within the past 6 months).&#xD;
&#xD;
          -  Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory&#xD;
             drugs (NSAIDs).&#xD;
&#xD;
          -  History of cardiovascular conditions.&#xD;
&#xD;
          -  Any other disease, gastrointestinal abnormality, metabolic dysfunction, physical&#xD;
             examination finding, or clinical laboratory finding giving reasonable suspicion of a&#xD;
             disease or condition that contraindicates the use of an investigational drug or that&#xD;
             may affect the interpretation of the results or render the patient at high risk from&#xD;
             treatment complications.&#xD;
&#xD;
          -  Receipt of any investigational agent, or participation in any other clinical study,&#xD;
             within 4 weeks before the start of study treatment.&#xD;
&#xD;
          -  Major surgery within 4 weeks before the start of study treatment, without complete&#xD;
             recovery.&#xD;
&#xD;
          -  Significant traumatic injury within 3 weeks before the start of study treatment (All&#xD;
             wounds must be fully healed prior to Day 1).&#xD;
&#xD;
          -  Uncontrolled excess calcium levels.&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  Inadequate organ function&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>the First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yet-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>January 8, 2014</study_first_submitted>
  <study_first_submitted_qc>January 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2014</study_first_posted>
  <last_update_submitted>March 10, 2017</last_update_submitted>
  <last_update_submitted_qc>March 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

